Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2023 08:30 ET | Source: Veru Inc.

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for...
September 08, 2020 08:35 ET | Source: Celsion CORP

Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study

Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...
April 14, 2014 07:30 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC

NORTHVALE, N.J., April 14, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with...
March 03, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials

NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are...
February 24, 2014 09:00 ET | Source: Nuvilex, Inc.

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be...
February 21, 2014 09:00 ET | Source: Nuvilex, Inc.

Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

NEW YORK, NY--(Marketwired - Feb 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the...